Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)
China flag China · Delayed Price · Currency is CNY
25.30
-0.10 (-0.39%)
May 6, 2026, 3:04 PM CST

SHE:300357 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Operating Revenue
1,0831,058921.46840.75894.88804.12
Other Revenue
3.923.923.947.441.143.58
1,0871,062925.39848.19896.02807.69
Revenue Growth (YoY)
15.91%14.81%9.10%-5.34%10.94%26.95%
Cost of Revenue
50.6350.5844.8140.1942.5134.44
Gross Profit
1,0361,012880.58808853.5773.25
Selling, General & Admin
487.1479.11434.65385.28359.63333.97
Research & Development
112.37117.1119.88112.2106.0287.93
Other Operating Expenses
7.249.637.844.574.533.78
Operating Expenses
610.58606.46563.23501.05471.43427.23
Operating Income
425.56405.37317.36306.95382.07346.02
Interest Expense
-0.81-0.79-1.06-1.31-0.44-0.36
Interest & Investment Income
53.5226.4535.8132.8728.3529.03
Currency Exchange Gain (Loss)
-0-000-0-0
Other Non Operating Income (Expenses)
0.52-0.32-0.34-0.26-0.15-0.17
EBT Excluding Unusual Items
478.8430.7351.76338.25409.82374.52
Gain (Loss) on Sale of Investments
4.783.432.43-0.67-0.88-0.1
Gain (Loss) on Sale of Assets
-0.630.57--0.27-
Asset Writedown
-5.11-5.11-1.42-0.58-43.23-0.1
Other Unusual Items
2.073.0611.728.9533.318.67
Pretax Income
480.53432.71365.06345.96398.75393
Income Tax Expense
67.4864.6260.7250.4363.0266.71
Earnings From Continuing Operations
413.05368.09304.34295.52335.73326.29
Minority Interest in Earnings
12.7812.8513.4814.6613.0511.7
Net Income
425.83380.94317.82310.18348.77337.99
Net Income to Common
425.83380.94317.82310.18348.77337.99
Net Income Growth
35.20%19.86%2.46%-11.06%3.19%21.38%
Shares Outstanding (Basic)
524524524524524524
Shares Outstanding (Diluted)
524524524524524524
Shares Change (YoY)
-0.01%-0.01%-0.00%--0.00%0.00%
EPS (Basic)
0.810.730.610.590.670.65
EPS (Diluted)
0.810.730.610.590.670.65
EPS Growth
35.21%19.87%2.46%-11.06%3.19%21.38%
Free Cash Flow
266.19270.9133.12154.61159.62236.33
Free Cash Flow Per Share
0.510.520.250.290.300.45
Dividend Per Share
0.2500.2500.2200.1850.2000.201
Dividend Growth
13.64%13.64%18.92%-7.50%-0.50%25.62%
Gross Margin
95.34%95.24%95.16%95.26%95.25%95.74%
Operating Margin
39.16%38.16%34.29%36.19%42.64%42.84%
Profit Margin
39.18%35.86%34.34%36.57%38.92%41.85%
Free Cash Flow Margin
24.49%25.50%14.39%18.23%17.82%29.26%
EBITDA
476.93455.18360.94338.38402.44366.11
EBITDA Margin
43.89%42.84%39.00%39.89%44.91%45.33%
D&A For EBITDA
51.3649.8143.5931.4320.3720.08
EBIT
425.56405.37317.36306.95382.07346.02
EBIT Margin
39.16%38.16%34.29%36.19%42.64%42.84%
Effective Tax Rate
14.04%14.93%16.63%14.58%15.80%16.97%
Revenue as Reported
1,0871,062925.39848.19896.02807.69
Source: S&P Global Market Intelligence. Standard template. Financial Sources.